Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Sells $908,600.00 in Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Shirley R. Kuhlmann sold 27,500 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the sale, the executive vice president now owns 119,184 shares in the company, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Collegium Pharmaceutical Stock Down 1.8 %

NASDAQ:COLL opened at $33.18 on Wednesday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The stock has a 50 day moving average of $30.57 and a 200-day moving average of $34.10. The firm has a market capitalization of $1.07 billion, a PE ratio of 14.30 and a beta of 0.82. Collegium Pharmaceutical, Inc. has a 52 week low of $28.39 and a 52 week high of $42.29.

Analyst Ratings Changes

Several brokerages recently weighed in on COLL. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Piper Sandler reiterated a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research note on Friday, January 10th. Finally, StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $43.80.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in COLL. TD Private Client Wealth LLC boosted its holdings in shares of Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after acquiring an additional 483 shares during the period. Foundry Partners LLC boosted its stake in Collegium Pharmaceutical by 3.3% during the 3rd quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company’s stock valued at $610,000 after purchasing an additional 509 shares during the period. CWM LLC grew its position in Collegium Pharmaceutical by 97.5% in the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after purchasing an additional 736 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 792 shares during the period. Finally, Harbor Capital Advisors Inc. increased its stake in shares of Collegium Pharmaceutical by 4.4% in the third quarter. Harbor Capital Advisors Inc. now owns 23,498 shares of the specialty pharmaceutical company’s stock valued at $908,000 after purchasing an additional 983 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.